KW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 antagonist KW-2478 appears to inhibit Hsp90, resulting in impaired signal transduction, inhibition of cell proliferation, and the induction of apoptosis in tumor cells. HSP90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. Check for active clinical trials or closed clinical trials using this agent.
HSP (HSP90) inhibitor Related Prodcuts:
Tanespimycin; Luminespib; Alvespimycin; Ganetespib; BIIB021; Onalespib; NVP-BEP800; SNX-2112; PF-04929113; XL888; Zelavespib (PU-H71); KRIBB11; VER-50589; Triptolide; NVP-HSP990; Dimethylenastron; Geldanamycin